Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Institut Catala Doncologia currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is confined to 1 distinct examiner and 1 distinct art unit, which indicates a targeted approach to their current intellectual property filings. The use of only 1 distinct art unit suggests that the company's pending innovation is specialized within a specific biological or pharmaceutical niche.
The busiest examiner for the portfolio is SALMON, KATHERINE D, who is responsible for 1 pending office action. For a practitioner, this concentration means that the immediate outcome for the company's pending matter is dependent on the individual examination style and prior art interpretation of this single examiner. Because there is only 1 pending office action, the applicant does not have the opportunity to compare different examiner responses within this technology area. This focus requires a prosecution strategy that is specifically tailored to the feedback provided by the 1 distinct examiner involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009885 | DNA Damage Repair Deficit in Cancer Cells | SALMON, KATHERINE D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009885 | DNA Damage Repair Deficit in Cancer Cells | SALMON, KATHERINE D | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18009885 | DNA Damage Repair Deficit in Cancer Cells | SALMON, KATHERINE D | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstitut Catala Doncologia has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katherine D Salmon has the most, with 1 of Institut Catala Doncologia's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
